# Diagnostics Polymers

> Diagnostics Polymers is a VC fund backing Medical, Big Data and Health Care. See 3 investments, check sizes, portfolio. Updated Sep 2026.

- Type: VC Fund
- Total investments: 3
- Last investment: Apr 2020
- Lead investor: 0%
- Last updated: Sep 2026

Diagnostics Polymers is a VC fund focused on Medical and Big Data. Investment Fund

## Round sizes

| Stage | Round size |
| --- | --- |
| Venture - Series Unknown | $1.2M–$1.9M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 33% |
| Big Data | 1 | 33% |
| Health Care | 1 | 33% |
| Life Science | 1 | 33% |
| Biotechnology | 1 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Convertible Note | 1 | 33% |
| Venture - Series Unknown | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $541.6K | Convertible Note | Apr 28, 2020 |  |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.2M | Venture - Series Unknown | Apr 06, 2018 |  |
| Metabolomic Diagnostics | Metabolomic Diagnostics is a deep-tech company specialized in the development of novel biomarker based diagnostic solutions for complex diseases. The company has developed an effective pipeline to firstly identify diagnostic biomarker panels and then translate these panels into clinical assays ready for application in the clinical laboratory.Thispipeline combines the biomarker multiplexing capabilities of Mass Spectrometry, a powerful analytical technology, with the company’s own informatics and statistics solutions to deliver diagnostic innovation. This is reflected in Metabolomic Diagnostics’ strong and versatile IP portfolio of technical innovations and biomarkers.Our VisionMetabolomic Diagnostics’ primary vision is to develop a portfolio of diagnostic solutions which can determine, early in a woman’s pregnancy,her risk of developing major complications much later in her pregnancy and thus enabling personalized care, adapted to each woman’s individual needs. Pregnancy complications like preeclampsia, gestational diabetes, preterm birth, and in-uterine growth restriction, all have the potential to severely impact on the well-being of mother and child.The company’s innovative diagnostic solutions will assist clinicians in re-imagining how these conditions are managed: our novel risk assessment tools are specifically developed in conjunction with prenatal care providers to ensure they make a difference that really matters. This in turn will enable clinicians to improve pregnancy outcomes globally.Our solutions will empower pregnant women: accurate pregnancy risk information will allow a pregnant woman, in partnership with her care provider, to determine what prenatal care is best for her pregnancy. | $1.9M | Venture - Series Unknown | Jun 16, 2016 |  |

3 of 3 investments shown.

## Co-investors
- [AIB Seed Capital Fund](https://shizune.co/investors/profile/aib-seed-capital-fund) — VC Fund, 3 deals together
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund, 3 deals together
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund, 2 deals together
- [Gotzee Ltd](https://shizune.co/investors/profile/gotzee-ltd) — VC Fund, 2 deals together
- [RebelBio](https://shizune.co/investors/profile/rebelbio-eu) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund

### Similar country
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund
- [NDRC](https://shizune.co/investors/profile/ndrc) — VC Fund
- [Act Venture Capital](https://shizune.co/investors/profile/act-venture-capital) — VC Fund

## Featured in investor lists
- [Life Science Investors in Ireland](https://shizune.co/investors/life-science-investors-ireland)
- [Life Science VC Funds in Ireland](https://shizune.co/investors/life-science-vc-funds-ireland)
- [Big Data VC Funds in Ireland](https://shizune.co/investors/big-data-vc-funds-ireland)
- [Medical VC Funds in Ireland](https://shizune.co/investors/medical-vc-funds-ireland)
- [Biotechnology VC Funds in Ireland](https://shizune.co/investors/biotechnology-vc-funds-ireland)
- [Health Care Investors in Ireland](https://shizune.co/investors/health-care-investors-ireland)

## FAQ

### What does Diagnostics Polymers invest in?

Diagnostics Polymers invests primarily in Medical, Big Data and Health Care startups, most often at Convertible Note and Venture - Series Unknown stage. Most of the 3 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Diagnostics Polymers's check size?

Diagnostics Polymers typically joins rounds of $1.2M–$1.9M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Diagnostics Polymers participates in.

### When did Diagnostics Polymers last invest?

The most recent investment recorded for Diagnostics Polymers closed in Apr 2020. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co